Mary-Kate Hayward

Mary-Kate Hayward

Auto-generated profile, based on publicly available information

Mary-Kate Hayward

Department of Surgery and Center for Bioengineering and Tissue Regeneration, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
KTKevin M. Tharp
Kevin M. Tharp
KKKelly Kersten
Kelly Kersten
OMOri Maller
Ori Maller
GTGreg A. Timblin
Greg A. Timblin
CSConnor Stashko
Connor Stashko
VWValerie M Weaver
Valerie M Weaver

8 June 2021 in Developmental Cell
Verified
Journal Article
Closed access
MHMary-Kate Hayward
Mary-Kate Hayward
JMJonathon M. Muncie
Jonathon M. Muncie
VWValerie M Weaver
Valerie M Weaver

15 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSConnor Stashko
Connor Stashko
MHMary-Kate Hayward
Mary-Kate Hayward
JNJason Northey
Jason Northey
NPNeil Pearson
Neil Pearson
AIAlastair J. Ironside
Alastair J. Ironside
VWValerie M Weaver
Valerie M Weaver
Intratumor heterogeneity associates with poor patient outcome. Stromal stiffening also accompanies cancer. Whether cancers demonstrate stiffness heterogeneity, and if this is linked to tumor cell heterogeneity remains unclear. We developed a method to measure the stiffness heterogeneity in human breast tumors that quantifies the stromal stiffness each cell experiences and permits visual registration with biomarkers of tumor progression. We present Spatially Transformed Inferential Force Map (STIFMap) which exploits computer vision to precisely automate atomic force microscopy (AFM) indentation combined with a trained convolutional neural network to predict stromal elasticity with micron-resolution using collagen morphological features and ground truth AFM data. We registered high-elasticity regions within human breast tumors colocalizing with markers of mechanical activation and an epithelial-to-mesenchymal transition (EMT). The findings highlight the utility of STIFMap to assess mechanical heterogeneity of human tumors across length scales from single cells to whole tissues and implicates stromal stiffness in tumor cell heterogeneity.

20 September 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
MHMary-Kate Hayward
Mary-Kate Hayward
MAMichael D. Allen
Michael D. Allen
JGJennifer J. Gomm
Jennifer J. Gomm
IGIain Goulding
Iain Goulding
CTClare L. Thompson
Clare L. Thompson
JJJ. Louise Jones
J. Louise Jones
Women with ductal carcinoma in situ (DCIS) have an increased risk of progression to invasive breast cancer. Although not all women with DCIS will progress to invasion, all are treated as such, emphasising the need to identify prognostic biomarkers. We have previously shown that altered myoepithelial cells in DCIS predict disease progression and recurrence. By analysing DCIS duct size in sections of human breast tumour samples, we identified an associated upregulation of integrin β6 and an increase in periductal fibronectin deposition with increased DCIS duct size that associated with the progression of DCIS to invasion. Our modelling of the mechanical stretching myoepithelial cells undergo during DCIS progression confirmed the upregulation of integrin β6 and fibronectin expression in isolated primary and cell line models of normal myoepithelial cells. Our studies reveal that this mechanostimulated DCIS myoepithelial cell phenotype enhances invasion in a TGFβ-mediated upregulation of MMP13. Immunohistochemical analysis identified that MMP13 was specifically upregulated in DCIS, and it was associated with progression to invasion. These findings implicate tissue mechanics in altering the myoepithelial cell phenotype in DCIS, and that these alterations may be used to stratify DCIS patients into low and high risk for invasive progression.

29 April 2025 in eLife preprints
Verified
Preprint
Open access
RNRachel Nakagawa
Rachel Nakagawa
ABAndrew Beardsley
Andrew Beardsley
SDSophia Durney
Sophia Durney
MHMary-Kate Hayward
Mary-Kate Hayward
VSVishvak Subramanyam
Vishvak Subramanyam
AGAndrei Goga
Andrei Goga
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRASG12C (G12Ci) pathway inhibition remain poorly understood. Our study reveals that acute response to EGFR/RAS/RAF-pathway inhibition is spatial and culture context specific. In vivo, EGFR mutant tumor xenografts shrink by > 90% following acute EGFRi therapy, and residual tumor cells are associated with dense stroma and have increased nuclear YAP. Interestingly, in vitro EGFRi induced cell cycle arrest in NSCLC cells grown in monolayer, while 3D spheroids preferentially die upon inhibitor treatment. We find differential YAP nuclear localization and activity, driven by the distinct culture conditions, as a common resistance mechanism for selective EGFR/KRAS/BRAF pathway therapies. Forced expression of the YAPS127A mutant partially protects cells from EGFR-mediated cell death in spheroid culture. These studies identify YAP activation in monolayer culture as a non-genetic mechanism of acute EGFR/KRAS/BRAF therapy resistance, highlighting that monolayer vs spheroid cell culture systems can model distinct stages of patient cancer progression.

28 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
RNRachel Nakagawa
Rachel Nakagawa
ABAndrew Beardsley
Andrew Beardsley
SDSophia Durney
Sophia Durney
MHMary-Kate Hayward
Mary-Kate Hayward
VSVishvak Subramanyam
Vishvak Subramanyam
AGAndrei Goga
Andrei Goga
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRAS G12C (G12Ci) pathway inhibition remain poorly understood. Our study reveals that acute response to EGFR/RAS/RAF-pathway inhibition is spatial and culture context specific. In vivo, EGFR mutant tumor xenografts shrink by > 90% following acute EGFRi therapy, and residual tumor cells are associated with dense stroma and have increased nuclear YAP. Interestingly, in vitro EGFRi induced cell cycle arrest in NSCLC cells grown in monolayer, while 3D spheroids preferentially die upon inhibitor treatment. We find differential YAP nuclear localization and activity, driven by the distinct culture conditions, as a common resistance mechanism for selective EGFR/KRAS/BRAF pathway therapies. Forced expression of the YAP S127A mutant partially protects cells from EGFR-mediated cell death in spheroid culture. These studies identify YAP activation in monolayer culture as a non-genetic mechanism of acute EGFR/KRAS/BRAF therapy resistance, highlighting that monolayer vs spheroid cell culture systems can model distinct stages of patient cancer progression. Graphical